INTRODUCTION AND OBJECTIVES: Level I evidence supports the utility of neoadjuvant chemotherapy (NAC) for muscle invasive bladder cancer (BCa). Although this evidence is derived primarily from phase III trials that used the combination of methotrexate/vinblastine/ doxorubicin/cisplatin (MVAC) or cisplatin/methotrexate/vinblastine (CMV), the alternative and less toxic regimen gemcitabine/cisplatin (GC) is currently used more commonly for NAC. Since dose dense (dd)-MVAC has mostly replaced traditional MVACOur primary endpoint was to assess the rate of pT0N0 and pT1N0 for patients with BCa treated with the accelerated or dose dense MVAC (ddMVAC) chemotherapy followed by radical cystectomy (RC) in this real-word multi-institutional cohort.
INTRODUCTION AND OBJECTIVES: Level I evidence supports the utility of neoadjuvant chemotherapy (NAC) for muscle invasive bladder cancer (BCa) . Although this evidence is derived primarily from phase III trials that used the combination of methotrexate/vinblastine/ doxorubicin/cisplatin (MVAC) or cisplatin/methotrexate/vinblastine (CMV), the alternative and less toxic regimen gemcitabine/cisplatin (GC) is currently used more commonly for NAC. Since dose dense (dd)-MVAC has mostly replaced traditional MVACOur primary endpoint was to assess the rate of pT0N0 and pT1N0 for patients with BCa treated with the accelerated or dose dense MVAC (ddMVAC) chemotherapy followed by radical cystectomy (RC) in this real-word multi-institutional cohort.
METHODS: We retrospectively reviewed records of patients with urothelial cancer who underwent ddMVAC and RC at seven contributing institutions from 2000-2015. Patients with cT2-4a,M0 BCa were included. Presence of cT3-4 disease, hydronephrosis, lymphovascular invasion and/or existence of sarcomatoid, or micropapillary features on the initial transurethral resection of bladder tumor specimen was defined as high-risk disease. Logistic regression models for prediction of pT0N0 and pT1N0 were generated for the entire cohort as well as for the cN0 subgroup. The multivariable Cox proportional hazards regression model for survival using post RC data was used to assess hazard ratios (HRs) for the variables of interest.
RESULTS: A total of 345 patients received ddMVAC chemotherapy during the study period. The observed rates of pT0N0 and pT1N0 were 30.4% and 49.3%, respectively among cN0 patients. On the multivariable regression model, the presence of more than one clinical high-risk element was associated with 70% (OR 0.30 95%CI (0.10-0.86); p¼0.02) reduction in the probability of achieving partial pathological response.
CONCLUSIONS: A complete response (pT0N0) was observed in one third of patients after neoadjuvant ddMVAC therapy, and a partial response (pT1N0) was observed in nearly half of the cases in this real-world experience with this regimen. To our knowledge, this represents the largest experience outside clinical trial settings.
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MP58-04 DENSE DOSE MVAC VERSUS GC IN PATIENTS WITH CT3-4A BLADDER CANCER TREATED WITH RADICAL CYSTECTOMY: A REAL WORLD EXPERIENCE INTRODUCTION AND OBJECTIVES: Level I evidence supports the utility of neoadjuvant chemotherapy (NAC) for muscle invasive bladder cancer (BCa). Although this evidence is derived primarily from phase III trials that used the combination of methotrexate/vinblastine/ doxorubicin/cisplatin (MVAC) or cisplatin/methotrexate/vinblastine (CMV), the alternative and less toxic regimen gemcitabine/cisplatin (GC) is currently used more commonly for NAC. Since dose dense (dd)-MVAC has mostly replaced traditional MVAC, we aimed to compare pathological response and survival rates in patients with locally advanced BCa receiving ddMVAC versus GC.
METHODS: We retrospectively reviewed records of patients with urothelial cancer who received NAC and underwent cystectomy at 19 contributing institutions from 2000-2013. Patients with cT3-4aN0M0 were selected for this analysis. The rate of pT0N0 and pT1N0 was compared between GC and ddMVAC regimens. A Multivariable Cox proportional hazards regression model for overall mortality was generated to evaluate hazard ratios (HRs) for variables of interest (age, LVI, hydronephrosis, type of chemotherapy regimen, surgical margin).
RESULTS: Of 1865 patients undergoing NAC and RC during the study period, 319 met our inclusion criteria (table 1) . A significantly lower rate of pT0N0 was observed in the GC arm compared to ddMVAC (14.6% vs. 28.0%; p¼0.005). The rate of pT1N0 was 30.1% for GC compared to 41.0% for ddMVAC (p¼0.07). The Kaplan-Meier mean estimate of overall survival for GC and ddMVAC patients was 4.2 and 7.0 years, respectively (p¼0.001). In multivariable cox regression analysis, GC patients were at higher risk of death compared to ddMVAC patients (HR 1.9, 95%CI (1.2-3.1); p¼0.006). Presence of LVI (HR 2.1, 95%CI (1.2-3.6); p¼0.007), hydronephrosis (HR 1.9, 95%CI (1.3-2.9); p¼0.002) and positive surgical margin (HR 1.4, 95%CI (1.2-1.7); p<0.001) were also associated with higher risk of death.
CONCLUSIONS: In our retrospective cohort of locally advanced BCa patients, ddMVAC was associated with a higher rate of pathologic down-staging response and improved longer survival when compared to GC. A clinical trial is warranted to validate these hypothesis-generating results superiority of neoadjuvant ddMVAC in patients with locally advanced BCa. Vol. 197, No. 4S, Supplement, Sunday, May 14, 2017 THE JOURNAL OF UROLOGY â e773
Source INTRODUCTION AND OBJECTIVES: MIBC patients who respond to cisplatin based NAC, defined as stage <ypT2 at cystectomy, exhibit a high 5 year cancer specific survival (CSS) of up to 90%. In contrast, non-responders (stage ¼ypT2 at cystectomy) exhibit a worse CSS (30-40%) than cystectomy alone, highlighting the need for predictors of NAC response. Recent MIBC studies have identified a gene expression based taxonomy (basal versus luminal phenotypes) similar to that of breast cancer. We evaluated the role of such a classification using immunohistochemical stains in a NAC cohort of MIBC.
METHODS: Pre-treatment tissues from a cohort of 71 NAC treated MIBC patients at our institution between 2000 and 2013 were incorporated in tissue microarray and stained for CK5/6 and GATA3 (Ventana Medical Systems, AZ). Cases were assigned as luminal or basal phenotype based on the extent (70% cut off) of tumor cells with ¼2+ staining intensity, Figure 1A . We limited our analysis of CSS to the 40 patient who were able to tolerate ¼2 doses of NAC to avoid the confounding effect of patients who were not adequately dosed.
RESULTS: As expected, there was an inverse association for CK5/6 and GATA3: 77% (43/56) of strong GATA3 cases exhibited weak/negative CK5/6 staining, most consistent with the luminal phenotype, and 73% (11/15) of the GATA3 weak/negative cases exhibited strong CK5/6, most consistent with the basal phenotype (Fisher's exact p-value 0.0003). Interestingly there was a~2 fold enrichment of basal the phenotype in cases with residual MIBC following NAC, Figure 1B .
CONCLUSIONS: Our results suggest a differential responsiveness to NAC for MIBC based on assignment of basal and luminal phenotypes. The current findings should be further evaluated taking P53 gene expression status into account, given previous suggestion of chemotherapy resistance in P53 intact (p53-Like) MIBC. Furthermore, comparison to IHC luminal/basal MIBC phenotypes in our cohort of cystectomy only treated patients is ongoing to help discern the prognostic vs predictive role of this classification for NAC. 
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INTRODUCTION AND OBJECTIVES:
It has been reported that lymph node density is superior to TNM nodal status in predicting oncologic outcome after radical cystectomy (RC) for urothelial carcinoma of bladder (UCB). The survival benefits of adjuvant chemotherapy (AC) following RC according to LND were assessed in this study.
METHODS: Of 888 consecutive UCB patients undergoing RC with pelvic lymph node dissection (PLND), 164 (18.5%) received the AC. After controlling preoperative and postoperative clinical and pathological variables, recurrence-free (RFS) and cancer-specific survival (RFS) after RC with PLND were compared between the AC and non AC groups.
RESULTS: After the strict propensity scored matching (both discard, caliper¼0.1), 130 patients with AC were not significantly different with 130 matched patients without AC, in age (62.5 vs. 61.8 years), pT stage (pT3, 78.5 vs. 77.7%), pN stage (pN1, 23.8 vs. 30.8% ;pN2, 32.3 vs. 32.3%), tumor grade (high, 95.4 vs. 87.7%), carcinoma in situ (23.1 vs. 28.5%), lymphovascular invasion (62.3 vs. 58.5%), positive surgical margin (10.0 vs. 10.0%), dissected LN number (19.8 vs. 22.4) , and LN density (0.14 vs. 0.15; p range, 0.071-1.000). During median 43.0 months follow-up after the RC with PLND, median RFS of AC group was similar to that of non AC group (37.0 vs. 30.0 months, p¼0.612). CSS were not also different between two groups (60.0 vs. 55.0 months, p¼0.313). However, better RFS (20.0 vs. 9.0 months, p¼0.008) and CSS (44.0 vs. 18.0 months, p¼0.009) of AC group were observed in subgroup of patients with LND 0.05 (N¼122). CONCLUSIONS: After adjusting the possible confounders and selection biases, AC demonstrated better oncological outcomes in patients with LND 0.05. Patients with LND 0.05 on final pathology should be considered the AC for better survival outcomes.
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